-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
- Between January 15, 2015 and July 6, 2020, a total of 101 post-cerebral hemorrhage patients were recruited (median age 78 years [IQR 73-83]; 55[54%] males and 46[46%] Female; 100 [99%] White and 1 [1%] Black), with a median age of 46 days (IQR 21-74)
Literature source: Schreuder FHBM, van Nieuwenhuizen KM, Hofmeijer J, et al.
Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial .
Lancet Neurol.
2021;20(11):907-916.
doi:10.
1016/S1474-4422(21)00298-2 Schreuder FHBM, van Nieuwenhuizen KM, Hofmeijer J, et al.
Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial.
Lancet Neurol.
2021;20(11):907-916.
doi:10.
1016/S1474-4422(21) 00298-2
Leave a message here